Compositions and methods for treating alzheimer's disease
US-2024376452-A1 · Nov 14, 2024 · US
Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
US9101646B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9101646-B2 |
| Application number | US-75258110-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 1, 2010 |
| Priority date | Jan 17, 2002 |
| Publication date | Aug 11, 2015 |
| Grant date | Aug 11, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.
First claim
Opening claim text (preview).
The invention claimed is: 1. A bispecific antisense oligodeoxynucleotide consisting of Seq. ID No. 5, wherein the oligodeoxynucleotide is modified to enhance in vivo stability. 2. The oligodeoxynucleotide of claim 1 , wherein the oligodeoxynucleotide is a phosphorothioate derivative. 3. The oligodeoxynucleotide of claim 1 , wherein the oligodeoxynucleotide has 2′-O-methoxyethyl substitutions on the backbone. 4. A pharmac…
Assignees
Inventors
Classifications
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9101646B2 cover?
- Bispecific antisense oligonucleotides which consist essentially of a sequence of bases that is complementary to portions of both the gene encoding human IGFBP-2 and the gene encoding human IGFBP-5 are useful in as antisense therapeutics in the treatment of endocrine-regulated cancers.
- Who is the assignee on this patent?
- Gleave Martin, Signaevsky Maxim, Univ British Columbia
- What technology area does this patent fall under?
- Primary CPC classification A61K31/713. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 11 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).